Resultado de búsqueda
Hace 2 días · Novel potassium-competitive acid blockers (P-CABs) have emerged as effective acid-suppressive drugs in recent years, replacing proton pump inhibitors (PPIs). We aim to compare the efficacy and safety of P-CABs versus PPIs in the treatment of peptic ulcers with or without Helicobacter pylori (H. pylori) infection. We searched in PubMed, Embase, WOS, Cochrane Library, ClinicalTrials.gov, CNKI ...
Hace 3 días · Exploring Potassium Competitive Acid Blockers (PCABs) as a Mechanism in Acid-Related GI Diseases. Authors: Brooks D. Cash, MD CME / ABIM MOC Released: 9/28/2022 THIS ACTIVITY HAS EXPIRED FOR CREDIT; Valid for credit through: 9/28/2023, 11:59 PM EST
Hace 21 horas · Published 2024.05.30 11:27. Yunovia, a new drug research and development subsidiary of Ildong Pharmaceutical, said Thursday that it has signed a joint development and licensing agreement with Daewon Pharmaceutical to develop a new drug for peptic ulcer disease based on P-CAB (Potassium-Competitive Acid Blockers). Under the agreement, Daewon ...
Hace 5 días · Moreover, other potent acid-suppressive drugs, such as potassium-competitive acid blockers, may warrant further investigation in managing chronic cough. Conclusion
Hace 21 horas · Helicobacter pylori has a big sway when peptic ulcers are concerned. For its eradication, different protocols have been approved. Among which, the tripartite therapy protocol which embraces vonoprazan as potassium competitive acid blocker in combination with amoxicillin and metronidazole as antibiotics. An environmentally benign HPLC method is addressed in order to simultaneously determine ...
Hace 2 días · Efficacy and safety data of potassium-competitive acid blockers for the treatment of GERD and EE. Have greater competence related to. Selecting evidence-based treatment for patients with GERD and EE. Improved performance associated with identifying patients who require upper endoscopy for the differential diagnosis of EE.
Hace 3 días · The success rate of primary eradication therapy that includes vonoprazan (a potassium-competitive acid blocker) instead of a proton pump inhibitor is currently acceptable, but the...
